UBS Group AG boosted its holdings in OPKO Health, Inc. (NASDAQ:OPK – Free Report) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,352,784 shares of the biotechnology company’s stock after acquiring an additional 577,248 shares during the quarter. UBS Group AG owned about 0.70% of OPKO Health worth $6,745,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Swiss Life Asset Management Ltd bought a new stake in OPKO Health in the third quarter worth about $30,000. CIBC Bancorp USA Inc. purchased a new position in OPKO Health in the 3rd quarter worth about $68,000. Verition Fund Management LLC increased its stake in OPKO Health by 57.0% in the 3rd quarter. Verition Fund Management LLC now owns 79,534 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 28,884 shares in the last quarter. SIH Partners LLLP increased its stake in OPKO Health by 116.3% in the 3rd quarter. SIH Partners LLLP now owns 150,125 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 80,706 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in OPKO Health by 97.0% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 77,886 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 38,352 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors.
OPKO Health Trading Up 1.8%
NASDAQ:OPK opened at $1.15 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.61 and a quick ratio of 3.17. OPKO Health, Inc. has a fifty-two week low of $0.98 and a fifty-two week high of $1.60. The stock’s 50-day moving average is $1.16 and its two-hundred day moving average is $1.25. The stock has a market cap of $868.36 million, a PE ratio of -4.26 and a beta of 1.42.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on OPK. Wall Street Zen cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Barrington Research cut OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings raised OPKO Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $1.55.
Check Out Our Latest Report on OPKO Health
About OPKO Health
OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.
In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.
Featured Stories
- Five stocks we like better than OPKO Health
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OPKO Health, Inc. (NASDAQ:OPK – Free Report).
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
